Hoth Therapeutics Inc. (NASDAQ: HOTH) is -5.49% lower on its value in year-to-date trading and has touched a low of $1.56 and a high of $7.20 in the current 52-week trading range. The HOTH stock was last observed hovering at around $2.24 in the last trading session, with the day’s gains setting it 0.03% off its average median price target of $10.00 for the next 12 months. It is also 77.3% off the consensus price target high of $10.00 offered by 1 analysts, but current levels are 77.3% higher than the price target low of $10.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $2.27, the stock is 19.98% and 26.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.61 million and changing 1.34% at the moment leaves the stock -8.26% off its SMA200. HOTH registered -54.19% loss for a year compared to 6-month loss of -14.50%. The firm has a 50-day simple moving average (SMA 50) of $1.8242 and a 200-day simple moving average (SMA200) of $2.1662.
The stock witnessed a 21.74% gain in the last 1 month and extending the period to 3 months gives it a 20.43%, and is -2.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.68% over the week and 8.94% over the month.
Distance from 52-week low is 45.51% and -68.47% from its 52-week high.
Hoth Therapeutics Inc. (HOTH) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Hoth Therapeutics Inc. (HOTH) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Hoth Therapeutics Inc. is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.1.The EPS is expected to shrink by -69.50% this year.
Hoth Therapeutics Inc. (HOTH) Top Institutional Holders
15 institutions hold shares in Hoth Therapeutics Inc. (HOTH), with 5.09M shares held by insiders accounting for 37.89% while institutional investors hold 2.52% of the company’s shares. The shares outstanding are 13.44M, and float is at 8.35M with Short Float at 0.29%. Institutions hold 1.56% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 79208.0 shares valued at $0.16 million. The investor’s holdings represent 0.59% of the HOTH Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 49687.0 shares valued at $97883.0 to account for 0.37% of the shares outstanding. The other top investors are Blackrock Inc. which holds 26719.0 shares representing 0.20% and valued at over $52636.0, while Susquehanna Fundamental Investments, LLC holds 0.14% of the shares totaling 19006.0 with a market value of $37441.0.
Hoth Therapeutics Inc. (HOTH) Insider Activity
A total of 0 insider transactions have happened at Hoth Therapeutics Inc. (HOTH) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Hayes Anthony, the company’s 10% Owner. SEC filings show that Hayes Anthony sold 400,000 shares of the company’s common stock on May 26 at a price of $1.25 per share for a total of $0.5 million. Following the sale, the insider now owns 1.13 million shares.